Get personalized recommendations to improve your portfolio.
Simulate financial scenarios and prepare for your future.
Plan, organize, and secure your legacy.
Easily track and manage your entire portfolio.
Personalized recommendations for tax-loss harvesting.
Hedge fund-inspired tools powered by AI.
Palvella Therapeutics, Inc. (PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare genetic skin diseases. Its lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is in Phase 3 and Phase 2 clinical trials for microcystic lymphatic malformations and cutaneous venous malformations, respectively.
XTX Topco Ltd has acquired 17,701 shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA), a new stake valued at approximately $399,000, boosting institutional ownership to 40.11%. Despite missing quarterly EPS estimates, analysts maintain a "Buy" rating with an average target price of $125.00, and several firms have raised their price targets. Insider activity includes COO Kathleen Goin selling shares worth over $370,000.
The average one-year price target for Palvella Therapeutics (NasdaqCM:PVLA) has been raised by 15.61% to $133.70 per share, up from $115.65. This new target represents a 33.05% increase from the last closing price of $100.49. Institutional ownership in PVLA has also increased, with 166 funds reporting positions, reflecting a bullish outlook with a put/call ratio of 0.05.
Analysts from Truist Financial and H.C. Wainwright have issued bullish ratings on several healthcare stocks. Adicet Bio (ACET) and Palvella Therapeutics (PVLA) both received "Buy" ratings from Truist Financial analysts, with Palvella showing a significant upside potential. Neuphoria Therapeutics (NEUP) also maintained a "Buy" rating from an H.C. Wainwright analyst.
Palvella Therapeutics reported its third-quarter 2025 financial results, highlighting advancements in its QTORIN™-derived therapies for four rare skin diseases. The company expects top-line results for its Phase 2 TOIVA trial in cutaneous venous malformations by mid-December 2025 and for its Phase 3 SELVA trial in microcystic lymphatic malformations in Q1 2026. Palvella also expanded its pipeline to include angiokeratomas and disseminated superficial actinic porokeratosis (DSAP), with cash and cash equivalents of $63.6 million expected to fund operations into the second half of 2027.
Palvella Therapeutics has received its second year of FDA grant funding for the Phase 3 Qtorin trial. This funding supports the ongoing clinical development of QTORIN rapamycin, a lead product candidate for treating serious, rare genetic skin diseases. The company is actively progressing trials for microcystic lymphatic malformations and cutaneous venous malformations, and recently expanded its development into angiokeratomas.
Palvella Therapeutics (NASDAQ: PVLA) announced the expansion of its QTORIN™ rapamycin development program to include Clinically Significant Angiokeratomas, a rare lymphatic disease affecting over 50,000 U.S. patients with no FDA-approved therapies. The company plans to initiate a Phase 2 trial in the second half of 2026, following FDA discussions in H1 2026. This marks QTORIN™ rapamycin's third target indication, with top-line results from ongoing microcystic lymphatic malformations (Phase 3 SELVA) and cutaneous venous malformations (Phase 2 TOIVA) studies expected in December 2025 and Q1 2026, respectively.
All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.